75182 Federal Register / Vol. 75, No. 231 / Thursday, December 2, 2010 / Notices 

peptide analogs via on resin click 

chemistry. In preparation. 

Patent Status: U.S. Provisional 

Application No. 61/347,038 filed 21 

May 2010 (HHS Reference No. E–130– 

2010/0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Whitney Hastings; 

301–451–7337; hastingw@mail.nih.gov. 

Novel Therapeutic Compounds for 

Treatment of Cancer and Immune 

Disorders 

Description of Invention: The global 

market for cancer therapeutics is over 

$40 billion and is anticipated to 

continue to rise in the future. There 

remains a significant unmet need for 

therapeutics for cancers that affect 

blood, bone marrow, and lymph nodes 

and the immune system, such as 

leukemia, multiple myeloma, and 

lymphoma. The proteasome inhibitor 

bortezomib, which may prevent 

degradation of pro-apoptotic factors 

permitting activation of programmed 

cell death in neoplastic cells dependent 

upon suppression of pro-apoptotic 

pathways, has been a successful mode 

of treatment for such cancers. However, 

some patient’s cancers have been found 

to be resistant to the drug. 

Researchers at the National Institutes 

of Health have developed novel 

hydrazone and diacyl hydrazine 

compounds that are inhibitors of the 

endoplasmic reticulum-associated 

protein degradation (ERAD) pathway. 

These compounds preferentially target 

the proteasome assistant ATPase p97/ 

VCP at a site independent of nucleotide 

binding. The researchers have shown 

that these ERAD inhibitors can induce 

cancer cell death and can also synergize 

with bortezomib in cytotoxic activity. In 

addition to treating diseases or disorders 

in which inhibition of the ERAD 

pathway is an effective therapy, these 

novel compounds may also be useful in 

the study of protein degradation. 

Advantages: 

• Development of therapies against 

tumors that are resistant to bortezomib. 

• Use in therapies in combination 

with proteasome inhibitors. 

• Development of 

immunosuppressive therapies that 

target the ubiquitin proteasome system. 

• Studies of the mechanism of protein 

degradation and other biological 

processes that involve the p97 ATPase. 

• Bioprobes to detect endoplasmic 

reticulum (ER) structures in live cells. 

Advantages: 

• Potent anti-tumor activity. 

• Simpler chemical structure makes 

synthesis easier and more cost-effective 

than previous ERAD inhibitors. 

• Retain activity against bortezomibresistant cells and can synergize with 

bortezomib. 

• Fluorescent. 

• High affinity for the ER. 

Development Status: Pre-clinical. 

Inventors: Adrian Wiestner (NHLBI), 

William Trenkle (NIDDK), Yihong Ye 

(NIDDK) et al. 

Relevant Publications: 

1. Qiuyan Wang et al. ERAD inhibitors 

integrate ER stress with an 

epigenetic mechanism to activate 

BH3-only protein NOXA in cancer 

cells. Proc Natl Acad Sci USA 2009 

Feb 17;106(7):2200–2205. [PubMed: 

19164757] 

2. Qiuyan Wang et al. The ERAD 

inhibitor Eeyarestatin I is a 

bifunctional compound with a 

membrane-binding domain and a 

p97/VCP inhibitory group. PloS 

ONE 2010, in press. 

Patent Status: U.S. Provisional 

Application No. 61/266,760 filed 04 Dec 

2009 (HHS Reference No. E–291–2009/ 

0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Surekha Vathyam, 

Ph.D.; 301–435–4076; 

vathyams@mail.nih.gov. 

Targeted Anti-Cancer Compounds for 

Treating Chromosomal Instability 

Syndromes 

Description of Invention: At $47 

billion, cancer is one of the largest, 

fastest growing markets in the 

pharmaceutical industry. There remains 

a significant unmet need for new 

therapeutics that target cancer cells 

while sparing normal cells. Cancer cells 

show higher levels of DNA damage than 

normal cells, and therefore rely more 

heavily than normal cells on DNA repair 

mechanisms for survival. There is a 

particular need for cancer therapies for 

cancer-prone chromosomal instability 

syndromes such as Ataxia 

Telangiectasia, Nijmegen Breakage, 

Bloom, and Fanconi’s anemia, which 

result from dysfunctional DNA repair 

systems. 

Researchers at Columbia University 

and the National Cancer Institute (NCI) 

have developed compositions and 

methods of useful in the treatment of 

cancer and in the sensitization of cancer 

cells to cancer therapy. The 

compositions target the MRE11– 

RAD50–NBS1 (MRN) complex, a DNA 

repair complex essential for sensing and 

responding to DNA damage. 

Given the dependency of cancer cells 

on DNA repair systems, they are 

susceptible to compositions that inhibit 

DNA damage repair. Thus, cancers that 

already have one or more defects in 

DNA repair systems, such as those from 

patients with chromosomal instability 

syndromes, are effectively treated with 

the present compositions. 

Applications: Development of 

treatments for cancer. 

Development Status: Pre-clinical. 

Inventors: Levy Kopelovich (NCI) 

et al. 

Relevant Publication: A Dupre ́ et al. A 

forward chemical genetic screen reveals 

an inhibitor of the Mre11–Rad50–Nbs1 

complex. Nat Chem Biol. 2008;4(2):119– 

125. [PubMed: 18176557] 

Patent Status: 

• U.S. Provisional Application No. 

61/203,377 filed 22 Dec 2008 (HHS 

Reference No. E–154–2009/0–US–01). 

• International Application No. PCT/ 

US09/69171 filed 22 Dec 2009, which 

published as WO 2010/075372 on 01 Jul 

2010 (HHS Reference No. E–154–2009/ 

0–PCT–02). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Patrick P. McCue, 

Ph.D.; 301–435–5560; 

mccuepat@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, Division 

of Cancer Prevention, Chemopreventive 

Agent Development Research Group, is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

agents for the prevention and treatment 

of cancer. Please contact John Hewes, 

Ph.D. at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Dated: November 24, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–30278 Filed 12–1–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Citizenship and Immigration 

Services 

Agency Information Collection 

Activities: Form I–914, Extension of a 

Currently Approved Information 

Collection; Comment Request 

ACTION: 30-Day Notice of Information 

Collection under Review: Form I–914 

and Supplements A and B, Application 

for T Nonimmigrant Status; Application 

for Immediate Family Member of T–1 

Recipient; and Declaration of Law 

Enforcement Officer for Victim of 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES

Federal Register / Vol. 75, No. 231 / Thursday, December 2, 2010 / Notices 75183 

Trafficking in Persons; OMB Control No. 

1615–0099. 

The Department of Homeland 

Security, U.S. Citizenship and 

Immigration Services (USCIS) will be 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and clearance in accordance 

with the Paperwork Reduction Act of 

1995. The information collection was 

previously published in the Federal 

Register on September 8, 2010, at 75 FR 

54646, allowing for a 60-day public 

comment period. USCIS did not receive 

any comments for this information 

collection. 

The purpose of this notice is to allow 

an additional 30 days for public 

comments. Comments are encouraged 

and will be accepted until January 3, 

2011. This process is conducted in 

accordance with 5 CFR 1320.10. 

Written comments and/or suggestions 

regarding the item(s) contained in this 

notice, especially regarding the 

estimated public burden and associated 

response time, should be directed to the 

Department of Homeland Security 

(DHS), and to the Office of Management 

and Budget (OMB) USCIS Desk Officer. 

Comments may be submitted to: USCIS, 

Chief, Regulatory Products Division, 20 

Massachusetts Avenue, Washington, DC 

20529–2020. Comments may also be 

submitted to DHS via facsimile to 202– 

272–0997 or via e-mail at 

rfs.regs@dhs.gov, and to the OMB USCIS 

Desk Officer via facsimile at 202–395– 

5806 or via e-mail at 

oira_submission@omb.eop.gov. When 

submitting comments by e-mail please 

make sure to add OMB Control Number 

1615–0099 in the subject box. Written 

comments and suggestions from the 

public and affected agencies should 

address one or more of the following 

four points: 

(1) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(2) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

(4) Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses. 

Overview of This Information 

Collection 

(1) Type of Information Collection: 

Extension of a currently approved 

information collection. 

(2) Title of the Form/Collection: 

Application for T Nonimmigrant Status; 

Supplement A: Application for 

Immediate Family Member of T–1 

Recipient; and Supplement B: 

Declaration of Law Enforcement Officer 

for Victim of Trafficking in Persons. 

(3) Agency form number, if any, and 

the applicable component of the 

Department of Homeland Security 

sponsoring the collection: Form I–914; 

U.S. Citizenship and Immigration 

Services (USCIS). 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Primary: Individuals or 

Households. Form I–914 permits 

victims of severe forms of trafficking 

and their immediate family members to 

demonstrate that they qualify for 

temporary nonimmigrant status 

pursuant to the Victims of Trafficking 

and Violence Protection Act of 2000 

(VTVPA), and to receive temporary 

immigration benefits. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: Form I–914, 500 responses at 

2.25 hours per response; Supplement A, 

500 responses at 1 hour per response; 

Supplement B, 200 responses at .50 

hours per response. 

(6) An estimate of the total public 

burden (in hours) associated with the 

collection: 1,725 annual burden hours. 

If you need a copy of the information 

collection instrument, please visit the 

Web site at: http://www.regulations.gov. 

We may also be contacted at: USCIS, 

Regulatory Products Division, 20 

Massachusetts Avenue, NW., 

Washington, DC 20529–2020; 

Telephone 202–272–8377. 

Dated: November 24, 2010. 

Sunday Aigbe, 

Chief, Regulatory Products Division, U.S. 

Citizenship and Immigration Services, 

Department of Homeland Security. 

[FR Doc. 2010–30150 Filed 12–1–10; 8:45 am] 

BILLING CODE 9111–97–P 

DEPARTMENT OF THE INTERIOR 

Bureau of Land Management 

[IDI–36712] 

Notice of Proposed Withdrawal and 

Opportunity for Public Meeting; Idaho 

AGENCY: Bureau of Land Management, 

Interior. 

ACTION: Notice. 

SUMMARY: The Forest Service (FS) has 

filed an application with the Bureau of 

Land Management (BLM) requesting the 

Assistant Secretary of the Interior for 

Land and Minerals Management to 

withdraw 10 acres of public land 

adjacent to the Clearwater National 

Forest from mining to protect the Lenore 

Tree Improvement Area near Orofino, 

Idaho and adjacent to the Clearwater 

River. This notice segregates the land for 

up to 2 years from settlement, sale, 

location or entry under the United 

States mining laws. The land will 

remain open to mineral leasing and to 

all activities currently consistent with 

applicable Forest plans and those 

related to the exercise of valid existing 

rights. This parcel of land has been 

withdrawn for FS use since 1990 for 

genetic seedling testing purposes. This 

proposed withdrawal covers the same 

10 acres that were withdrawn for FS use 

under Public Land Order (PLO) No. 

6799, BLM Serial Number IDI–26701, 

published on Friday, September 14, 

1990 in the Federal Register (55 FR 

37878). Due to an administrative 

oversight on the part of the FS, PLO 

6799 expired before an extension of the 

withdrawal can be processed. Therefore, 

the FS is requesting a new 20-year 

withdrawal covering the same area. 

DATES: Comments and request for a 

public meeting must be received by 

March 2, 2011. 

ADDRESSES: Comments and meeting 

requests should be sent to the Forest 

Supervisor, Clearwater National Forest, 

12730 Highway 12, Orofino, Idaho 

83544. 

FOR FURTHER INFORMATION CONTACT: 

Laura Summers, BLM Idaho State 

Office, 208–373–3866 or Scott Bixler, 

Forest Service, (406) 329–3655. 

SUPPLEMENTARY INFORMATION: The FS 

has filed an application to withdraw the 

following described public land from 

settlement, sale, location and entry 

under the United States mining laws, 

subject to valid existing rights: 

Boise Meridian 

Clearwater National Forest 

T. 37 N., R. 1 W., 

Sec. 32, N1⁄2S1⁄2NW1⁄4SW1⁄4. 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES